The Monoamine Oxidase pipeline drugs market research report outlays comprehensive information on the Monoamine Oxidase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Monoamine Oxidase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Infectious Disease, Oncology, and Immunology which include the indications Parkinson’s Disease, Alzheimer’s Disease, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Coronavirus Disease 2019 (COVID-19) Pneumonia, Glioma, and Autoimmune Disorders. It also reviews key players involved in Monoamine Oxidase targeted therapeutics development with respective active and dormant or discontinued products.
The Monoamine Oxidase pipeline targets constitutes close to 34 molecules. Out of which, approximately 26 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 2, 4, 4, 1, 11, and 3 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 4, and 3 molecule.
Monoamine Oxidase overview
Monoamine oxidase (MAO) is a family of enzymes that break down neurotransmitters in the brain. MAOs are responsible for degrading serotonin, dopamine, and norepinephrine. They are located in the outer membrane of mitochondria throughout the brain. Monoamine oxidase inhibitors (MAOIs) prevent MAOs from breaking down neurotransmitters.
For a complete picture of Monoamine Oxidase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
